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inflammatory chemokines provide axes for
effective recruitment of therapeutic adult
stem cell into muscles
Vitali Alexeev1, Jacquelyn Olavarria1, Paolo Bonaldo2, Luciano Merlini3 and Olga Igoucheva1*
Abstract
Background: Congenital muscular dystrophies (CMD) are a clinically and genetically heterogeneous group of
neuromuscular disorders characterized by muscle weakness. The two most prevalent forms of CMD, collagen VI-related
myopathies (COL6RM) and laminin α2 deficient CMD type 1A (MDC1A), are both caused by deficiency or dysfunction of
extracellular matrix proteins. Previously, we showed that an intramuscular transplantation of human adipose-derived stem
cells (ADSC) into the muscle of the Col6a1−/− mice results in efficient stem cell engraftment, migration, long-term survival,
and continuous production of the collagen VI protein, suggesting the feasibility of the systemic cellular therapy for
COL6RM. In order for this therapeutic approach to work however, stem cells must be efficiently targeted to the entire
body musculature. Thus, the main goal of this study is to test whether muscle homing of systemically transplanted ADSC
can be enhanced by employing muscle-specific chemotactic signals originating from CMD-affected muscle tissue.
Methods: Proteomic screens of chemotactic molecules were conducted in the skeletal muscles of COL6RM- and
MDC1A-affected patients and CMD mouse models to define the inflammatory and immune activities, thus, providing
potential markers of disease activity or treatment effect. Also using a pre-clinical animal model, recapitulating mild Ullrich
congenital muscular dystrophy (UCMD), the therapeutic relevance of identified chemotactic pathways was investigated
in vivo, providing a basis for future clinical investigations.
Results: Comprehensive proteomic screens evaluating relevant human and mouse skeletal muscle biopsies offered chemotactic
axes to enhance directional migration of systemically transplanted cells into CMD-affected muscles, including CCL5-CCR1/3/5,
CCL2-CCR2, CXCL1/2-CXCR1,2, and CXCL7-CXCR2. Also, the specific populations of ADSC selected with an affinity for the
chemokines being released by damaged muscle showed efficient migration to injured site and presented their therapeutic effect.
Conclusions: Collectively, identified molecules provided insight into the mechanisms governing directional migration and
intramuscular trafficking of systemically infused stem cells, thus, permitting broad and effective application of the therapeutic adult
stem cells for CMD treatment.
Keywords: Type VI collagen, COL6A1, Congenital muscular dystrophy, Adipose-derived stem cell, Cell-based therapy, Chemokines,
Chemotaxis
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Background
Alterations of extracellular matrix (ECM) or dysfunction
of ECM-associated proteins have been implicated in a var-
iety of diseases, notable among those are muscular dystro-
phies. Congenital muscular dystrophies (CMD) are a
clinically and genetically heterogeneous group of neuro-
muscular disorders characterized by muscle weakness
within the first 2 years of life [1]. The two most prevalent
forms of CMD, i.e., collagen VI (COL6)-related myop-
athies (COL6RM) and laminin α2 (LAMA2)-deficient
CMD type 1A (MDC1A), share a similar underlying dis-
ease mechanism, consisting in the deficiency or dysfunc-
tion of extracellular matrix (ECM) proteins. Both
disorders are unique among other hereditary myopathies
and considered hybrid disorders with clinical features at-
tributed to both muscle and connective tissue and often-
called disorders of myomatrix. Treatment options for
CMD patients are limited and mainly focused on address-
ing the clinical manifestations [2]. Due to the distinct cel-
lular origin of the proteins involved in the common CMD
forms, even though a range of therapeutic approaches
have been tested for traditional muscular dystrophies,
there is a need to develop treatment strategies that specif-
ically target muscle ECM alterations.
Adult stem cell-based therapy emerged as a promising
strategy for treating genetic diseases, including different
types of muscular dystrophies, in particular, Duchenne
muscular dystrophy [3, 4]. The majority of studies evalu-
ated the ability of muscle-derived stem cells or progeni-
tor cells, such as myoblasts, side population cells,
myogenic endothelial cells, pericytes, and mesoangio-
blasts, as well as cells from non-muscle tissues to replace
damaged muscle fibers [5–9]. However, transplanted
cells showed limited ability to regenerate muscle fibers
despite the production of missing proteins by trans-
planted cells but showed reduction of inflammation
through trophic effects elicited by transplanted cells.
Effective cell therapy of ECM-related CMD such as
COL6RM and MDC1A rests on the ability of the thera-
peutic cells to secrete normal ECM proteins that can
prevent muscle cell degeneration rather than on the po-
tential of stem cells to differentiate into muscle fibers.
Also, since the primary defect of COL6RM and MDC1A
are in muscle ECM but not in muscle cells the ability of
transplanted cells to differentiate into muscle cells is not
crucial and secondary to their function of supplying the
missing extracellular components. Until recently, bone
marrow was considered the main source for adult stem
cells. Recent advancements in stem cell isolation proto-
cols allowed discovery alternative repository of stem cells
such as subcutaneous fat. Similarly, to bone marrow-
derived mesenchymal stem cells, adipose-derived stem
cells (ADSC) can be obtained by less invasive methods,
differentiate into multiple linages, have relatively low
donor-site morbidity, and are available in large quan-
tities for procurement. Also, ADSC have potential as
immunoprivileged universal cells with capacity for the
allogeneic transplantation and reduced possibility of de-
veloping graft-versus-host disease. On special note,
ADSC produce a significant level of COL6 and to less
extent LAMA2 proteins, making these cells readily avail-
able for therapeutic intervention of CMD after local and
systemic administration [10].
Previously, we obtained a proof-of concept data show-
ing that human neonatal ADSC delivered intramuscu-
larly can participate in restoration of COL6 deficiency in
mouse model of COL6RM [10]. We have found that
transplantation of the xenogeneic ADSC leads to effi-
cient engraftment of adult stem cells into the interstitial
connective tissue of the skeletal muscles, long-term sur-
vival of stem cells up to 3 months in muscle environ-
ment, and continuous production of therapeutic the
COL6 protein. These findings suggested the possibility
of a durable clinical benefit following cell transplantation
and provided the scientific rationale for developing stem
cell therapy for CMD.
Effective therapy requires the delivery of therapeutic
stem cells to all body musculature, a problem that can-
not be easily overcome unless systemic transplantation
protocols are proved to be effective. Previous studies
showed that systemic transplantation of bone marrow-
and muscle-derived stem cells had a limited impact on
muscle cell replacement and improvement of murine
muscular dystrophy, partially due to poor cell recruit-
ment to the muscle tissue. Also, it is known that a large
fraction of systemically infused stem cells are passively
trapped in draining organs, such as lungs and liver [11].
For the same token, the relative heterogeneity of stem
cells, the limited repertoire of functional chemokine re-
ceptors on stem cell surface and possibly other factors
impede effective homing of stem cells to the skeletal
muscle tissue [12–14].
Currently, molecular mechanisms governing recruit-
ment of systemically transplanted stem cells from circu-
lation to the skeletal muscle are largely unknown.
However, prior studies have demonstrated that skeletal
muscles after experimental injury and dystrophic mus-
cles of mdx mice are characterized by an inflammatory
“molecular signature” in which CC and CXC chemo-
kines are prominent [15, 16]. The key mechanism that
regulates cell recruitment to distal anatomical sites and
migration of cells inside affected tissue is chemotaxis,
which depends on the signaling molecules termed che-
mokines. In the adult organism, expression of most che-
mokines is induced in response to physiologic stress or
damage. Being secreted, chemokines recruit leukocytes,
progenitor stem cells, and other cell types to the dis-
eased/damaged sites as part of host defense and repair
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mechanism. In physiological conditions, diverse insults
provoking muscle damage and repair trigger rapid and
significant leukocyte recruitment to the affected muscles
through activation of chemotactic factors produced by
muscle cells as wells as other resident cells such as mac-
rophages, known to be dominant generators of chemo-
kines and inflammatory and growth factors [17]. In turn,
the produced factors draw in inflammatory cells by
chemotaxis to clear debris and further promote growth
and differentiation of myoblasts and endothelial smooth
muscle cells required for tissue regeneration. In case of
genetic dystrophies such as CMD, sustained muscle fiber
damage during muscle contractions leads to fiber degen-
eration accompanied by inflammation and immune cell
infiltration. It is well known that a prominent feature of
CMD-affected muscle is a striking inflammatory infil-
trate of immune cells such as macrophages, neutrophils,
and T and B cells [18, 19]. Based on current knowledge
of leukocyte trafficking, it is plausible that systemically
transplanted ADSC can be recruited from circulation to
the CMD muscles by the activation of specific receptors
on the surface of transplanted ADSC, followed by trans-
muscular migration mediated by stem cell receptors
under influence of the CMD muscle-derived chemo-
kines. Through characterization of specific chemokines
secreted by CMD-damaged muscles and delivery of stem
cells with activated receptors to those chemokines,
therapeutic stem cells can potentially be delivered to
sites of disease-affected muscles and arrest further dam-
age to compromised muscle tissue.
In the current study, we performed comprehensive prote-
omic screens of chemotactic molecules in the skeletal mus-
cles of COL6RM- and MDC1A-affected patients and CMD
mouse models and identified chemokine receptor axes
available for recruitment of stem cells to the CMD-affected
skeletal muscles. Then, selected stem cell populations were
tested for their ability to promote disease-driven
chemotaxis-based muscle homing in vivo using pre-clinical
mouse model of COL6RM. Results of this investigation
could provide avenue for the potential clinical treatment of
CMD and related muscular disorders.
Methods
Mouse strains
All animal procedures were performed in accordance
with the “Guide for the Care and Use of Laboratory Ani-
mals” (National Institute of Health publication no. 86–
23) and approved by the Institutional Animal Care and
Use Committee of the Thomas Jefferson University.
Wild-type C57BL/6 mice were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA). NCr nude
spontaneous mutant (CrTac:NCr-Foxn1nu) (Taconic,
Derwood, MD, USA). DyW (B6.129S1(Cg)-Lama2t-
m1Eeng) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA). This model has
markedly reduced expression of a truncated LAMA2
chain and displays severe muscular dystrophy and per-
ipheral neuropathy. DyW newborn mice begin to show
evidence of disease by two weeks of age, are passive,
small, and emaciated, and demonstrate partial hind-leg
lameness and clasping and die by approximately 7 weeks
of age. Col6a1−/− mice were previously described [20].
Col6a1−/− possess a disruption of the gene encoding the
α1(VI) collagen chain, resulting in the lack of COL6 se-
cretion. The phenotype of the Col6a1−/− mice is mild.
Col6a1−/− mice have normal life span and somewhat
smaller size than the wild-type animals.
Muscle biopsies from CMD-affected patients
Muscle biopsies from healthy individuals were purchased
from ProteoGenex, Inc. (Culver City, CA, USA). Muscle
biopsies from CMD patients were obtained from
Congenital Muscular Dystrophy Tissue Repository
(CMD-TR, Milwaukee, WI, USA) and Dr. Luciano Mer-
lini (Bologna, Italy) according to ethical committee rules
and country’s regulations. No patient-identifiable infor-
mation was available to researchers. The study was not
determined as human subject research as per guidelines
of the Thomas Jefferson University IRB and as such did
not require ethics approval. Clinical features of the pa-
tients are presented in Table S1.
Tissue biopsies from CMD mouse models
The gastrocnemius muscle (GCM) was collected from
dyW and wild-type C57BL/6 mice at week one through
7 weeks of age, respectively. For each time point, biop-
sies from five animals were pooled and processed for the
total protein isolation as described previously [10]. Due
to the absence of significant muscle damage or inflam-
mation in the mild-phenotype Col6al −/− mice, muscle
damage was induced by administration of 10 μM cardio-
toxin (CTX, Sigma, St. Louis, MO, USA) to the right
GCM of the 6-month-old Col6a −/− and wild-type mice,
respectively. Animals were sacrificed at day 0 (baseline),
1, 3, 7, 14, and 21 days post-CTX treatments. Biopsies of
GCM from 5 animals in each cohort were pooled and
processed for total protein isolation.
Chemokine antibody arrays
Human Chemokine Antibody Arrays (RayBioTech, Nor-
cross GA, USA) and Proteome Profiler™ Mouse Chemo-
kine Antibody Array (R&D Systems, Minneapolis, MN,
USA) were used to assay skeletal muscle biopsies from pa-
tients affected with Bethlem myopathy, UCMD, MDC1A,
and mouse tissues derived from CMD mouse models,
dyW and Col6al −/− mice, respectively. Five hundred mi-
crograms of total protein were used to probe the chemo-
kine antibody array according to the manufacturer’s
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instructions. Chemokine antibody array membranes were
developed by standard enhanced chemiluminescence
techniques as advised by manufacturers. Acquisition of
signals on chemokine arrays was quantitatively determined
using ScanAlize version 2.50 (Stanford University) and
GEArray Expression Analysis Suite 2.0 software (SABios-
ciences, Frederick, MD, USA), which reads the images and
matches them to the corresponding protein on the array.
The net level of each protein was calculated by the mean of
the individual spot intensity minus the mean of the back-
ground intensity. To provide normalization, the average
level ratio of two principal proteins was determined and in-
troduced as a correction factor. Relative spot intensities are
presented as mean ± SD. Microsoft Excel (Microsoft, Red-
mond, WA, USA) was utilized for statistical analysis.
Isolation of mouse adipose-derived stem cells and tissue
culture conditions
Mouse subcutaneous fat was excised and maintained on
ice. Standard method for isolating and purifying ADSC
from the stromal vascular fraction (SVF) containing fibro-
blasts, pericytes, preadipocytes, monocytes, and macro-
phages, as well as smooth muscle, endothelial progenitor,
and red blood cells of the SVF, have been well established
and was employed here [10, 21]. Briefly, tissue was
digested in warmed DMEM/F12-Glutamax media
(Thermo/Fisher, Grand Island, NY, USA) supplemented
with 0.1% collagenase (Sigma. St. Louis, MO, USA) and
1% Penicillin/Streptomycin (Thermo/Fisher) while shak-
ing at 37 °C and 180 rpm for 1 h. To obtain a single cell
suspension, the digested tissue was applied to a 30-μm
mesh separation filter (Miltenyi Biotec, Auburn, CA,
USA). PBS+1% BSA solution was added to the mesh to
quench the enzyme and flush any remaining cells through
the filter. The suspension was centrifuged and the pellet
was resuspended in 1ml of DMEM/F12 and Glutamax+
10% FBS (Thermo/Fisher). Cells were plated in DMEM/
F12 and Glutamax plus 10% FBS (Invitrogen, Grand Is-
land, NY, USA) and grown to confluence. To remove
hematopoietic cells, cells then were depleted using mag-
netic separation beads (Miltenyi Biotec). Resultant
CD31−CD45− population defined as ADSC was designated
as first passage cells and was cultured in DMEM/F12-Glu-
tamax media supplemented with 10% FBS and penicillin/
streptomycin.
Generation and characterization of Ccr2- and Cxcr2-
overexpressing ADSC
Full-length mouse Ccr2 and Cxcr2 receptor with 3′
UTR was amplified from total mouse RNA via reverse
transcription reaction using Superscript II RT Kit (Invi-
trogen, Carlsbad, CA, USA) followed by PCR using PFU
II high fidelity polymerase (Agilent Technologies, Santa
Clara, CA, USA). Resultant cDNA was inserted into
pEF2-TOPO vector. Integrity of the promoter and
cDNA was verified by direct DNA sequencing. Minim-
ally cultured ADSC (passage 1–2) were nucleofected
with pEF1-mCcr2 and pEF1-mCxcr2 plasmids, respect-
ively, using Lonza nucleofection reaction (T-27 program,
nucleofection kit V; Lonza, Cologne, Germany). Further,
pool of Ccr2- and Cxcr2-expressing cells was selected
with Blasticidin (0.5 mg/ml; Invitrogen) for 10 days, re-
spectively. Expression of Ccr2 and Cxcr2 in selected cells
was confirmed by FACS and indirect immunofluores-
cence analyses. Receptor surface expression was deter-
mined by FACS using PE-conjugated antibodies. For
indirect immunofluorescence, Ccr2- and Cxcr2-
immunocomplexes were detected with Alexa-Fluor488-
conjugated secondary antibodies (Invitrogen). Nuclei
were counterstained with 4′,6-diamidino-2-phenyl indol
(DAPI; Sigma, St. Louis, MO, USA). Immunofluorescent
images were obtained on Nikon TS100F fluorescent
microscope (Nikon, Melville, NY, USA).
Transplantation of ADSC into mice under physiological
and pro-inflammatory conditions
All animal procedures were performed in accordance
with the “Guide for the Care and Use of Laboratory Ani-
mals” (National Institute of Health publication no. 86-
23) and approved by the Institutional Animal Care and
Use Committee of the Thomas Jefferson University. For
enforced migration of stem cells into skeletal muscle,
ADSC uniformly expressing Ccr2 were stably transduced
with Luciferase reporter gene. Native and Ccr2-
expressing ADSC were systemically administered via tail
vein injection into NCr nude mice, respectively, follow-
ing localized intramuscular administration with the
mouse recombinant Ccl2 chemokine into the left GCM.
For therapeutic assessment of Ccr2- and Cxcr2-ADSC in
physiological and pro-inflammatory conditions, 2.5 × 106
cells were labeled with a red lipophilic tracer DiOC18
(Molecular Probes, Grand Island, NY, USA) and system-
ically transplanted into 4 month old Col6a1−/− mice (n =
5/treatment/time point) via tail vein injection. To induce
pro-inflammatory injury, the left hindlimb was injected
with 10 μM cardiotoxin 3 days prior transplantation. The
right GCM was injected with PBS and used as a control
for natural homing. For analysis, transplanted mice were
euthanized by CO2 inhalation at predetermined time
points (4, 14, and 21 days) and muscle samples were col-
lected. In vivo imaging (IVIS) (Lumina XR, Caliper Life-
Sciences, Hopkinton, MA, USA) was performed at
indicated time points to determine the localization of
the transplants. At indicated time points, muscle biop-
sies were collected, embedded into OCT compound
(VWR, Pittsburgh, PA, USA), frozen, and cryosectioned
at a thickness of 10 μm. All samples were evaluated for
the presence of engrafted DiOC18-ADSC expressing
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cells using fluorescence microscopy. For indirect im-
munofluorescence analysis, cross-sections were stained
with rabbit polyclonal anti-α1(VI) collagen (kindly
provided by Timpl Laboratory) and rat monoclonal anti-
LAMA2 (clone 4H8–2; Enzo Life Sciences, Inc., Farm-
ingdale, NY, USA) antibodies. Immunocomplexes were
detected with AlexaFluor488- and AlexaFluor594-labeled
secondary antibodies (Invitrogen). Average number of
collagen α1(VI)-positive fibers was calculated and com-
pared between samples collected at different time points.
Multiple adjacent sections were analyzed within 20 ran-
dom, non-overlapping microscopic fields per sample. All
morphometric comparisons are presented as percentages
of untreated limb (baseline control) and analyzed for
statistical significance using the Student’s t test, with p
value less than 0.01 considered significant in all tests.
Statistical analysis
Data are presented as group mean values ± S.E.M. All
array data represent the average values obtained from at
least three independent experiments performed on sep-
arate occasions. Statistical comparisons were performed
using Student’s t test for independent samples or
ANOVA in the case of multiple comparisons. A value of
P < 0.05 was considered significant.
Results
Proteomic screens of chemokines in the skeletal muscles
of CMD patients
Proteome analysis consisted of skeletal muscle biopsies
from patients with confirmed diagnosis of Bethlem My-
opathy (BM, n = 5), Ulrich Congenital Muscular Dys-
trophy (UCMD, n = 8), and Merosin-deficient congenital
muscular dystrophy type 1A (MDC1A, n = 5). Patients
were from 2 to 67 years of age and presented a range of
clinical symptoms from mild to severe. The clinical char-
acteristics of CMD patients are summarized in Table S1.
Assay controls included skeletal muscle biopsies col-
lected from 18, 43, and 58-year-old healthy individuals
with no CMD history. The human chemokine array was
used to simultaneously survey 38 known human chemo-
kines. The data were analyzed by grouping the patients by
disease type (BM, UCMD and MDC1A) and represented
based on a comparison to muscle samples of healthy do-
nors. The ratio of mean pixel densities of individual che-
mokine in CMD samples to that in control group is
presented as the fold difference (Table 1, Fig. S1A). Ana-
lysis of biopsies collected from the healthy group demon-
strated that homeostatic muscles contain constitutively
low levels and limited repertoire of chemokines, with
CTAK (CCL27), GRO (CXCL1,2,3), IL-8 and IL-10,
MCP-1 (CCL2), MIP-1 beta (CCL4), NAP-2 (CXCL7),
and RANTES (CCL5) being above the minimal value of
the detection. Proteome profile of CMD-derived biopsies
reveled disease-related changes (Fig. 1). Cross analysis of
patient data showed that all examined muscle biopsies
share similar chemokine profile regardless of genetic
abnormality or severity of disease. Moreover, most
dominant molecules were found to be a pro-
inflammatory chemokines and common for all three
CMD types, those included NAP-2 (CXCL7), GCP
(CXCL6), GRO (CXCL1,2,3), RANTES2 (CCL5), and
MCP-1 (CCL2) (Fig. 1, Table 1). On special note, the
level of CCL5 was associated with CMD severity,
showing modest increase (1.7-fold) in BM-derived
muscles and considerably higher presence in muscles
of UCMD (5.7-fold) and MDC1A (11.0-fold) patients
(Table 1). However, prognostic value of this molecule will
require further statistical analysis in a larger cohort of pa-
tients with careful phenotypic evaluation. Collectively, ro-
bust analysis of CMD muscle-associated chemokines
revealed a distinct subset of chemokines that may contrib-
ute to the pathology of the major CMD types. These data
also revealed several chemotactic pathways that could be
further exploited for the effective recruitment and homing
of the systemically transplanted therapeutic stem cells to
CMD-affected muscles and the improvement of cell-based
therapies.
Table 1 Proteome analysis of selected chemokines in muscle
biopsies of CMD-affected patients
Chemokine Fold difference/controla
BM UCMD MDC1A
CCL28 6.6 6.1 7.9
CK beta 8-1 1.7 1.6 2.3
CTACK 1.2 1.2 1.9
CXCL-16 3.2 2.6 5.3
ENA-78 1.6 1.4 3.3
Eotaxin 2.6 2.2 6.2
GCP-2 1099.5 1151.4 1189.1
GRO 2.9 3.1 2.3
GRO-alpha 1.4 2.0 2.1
HCC-4 1.5 1.7 2.2
I-309 1.7 1.4 2.0
I-TAC 2.6 1.7 2.8
IL-8 0.5 0.7 1.2
IP-10 0.8 1.0 1.9
MCP-1 1.8 3.0 2.7
NAP-2 3.3 4.1 5.0
RANTES 1.7 5.7 11.0
aData represented as fold difference of CMD muscle vs healthy (control)
muscle. Each protein array was processed in an identical manner and the
number represents an average of triplicate experiments from 5 BM, 8 UCMD,
and 5 MDC1A muscle samples. Fold difference does not reflect quantity. BM
Bethlem myopathy, UCMD Ulrich congenital muscular dystrophy, MDC1A
Merosin-deficient congenital muscular dystrophy type 1A
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Proteome analysis of chemokines in LAMA2-deficient
mice
The Lama2 (dyW) mice recapitulate the clinical mani-
festations of MDC1A patients and display severe muscu-
lar dystrophy, with death around 5–7 weeks of age.
Proteomic screens of chemotactic molecules in the
gastrocnemius muscle (GCM) were conducted at differ-
ent stages of disease progression: initial (7–14 days),
acute (3–4 weeks), and terminal (5–6 weeks). Assay con-
trols were consisted of proteomic profiles utilizing the
GCM tissues from age-matched wild-type counterparts.
Densitometry data analysis of individual chemokine is
reported as the fold difference change of dyW compared
to wild-type samples. Evaluation of 25 known mouse
chemotactic molecules in the GCM of wild-type mice
showed constitutive presence of few chemokines at low
levels, mainly produced as a part of normal homeostasis
of muscle tissue (Fig. 2a, Fig. S1B). Contrary, analysis of
the GCM from dyW mice showed abundant presence of
several chemotactic molecules at all stages of disease
(Fig. 2b). Pairwise comparison of the GCM sampled
from dyW and normal mice revealed the significant in-
duction of seven distinct CC and CXC class chemokine
ligands, including CCL6, C5/C5a, RARRES2, CCL27, IL-
16, CCL2, CXCL1, CCL8, CCL12, CCL9/CCL10, and
CXCL12 (Table 2). Patterns of most identified chemo-
kines showed early induction as soon as 1 week of age
and maintained expression until termination point. Ana-
lysis of the diaphragm muscle (DM) sampled from dyW
and wild-type mice showed considerable presence of
CCL6 and RARRES2 and modest de-regulation of IL16,
CCL2, CXCL1, and CCL12 (data not shown). Interest-
ingly, the levels of some identified molecules were vari-
able depending on the tissue and did not necessarily
coincide with stage of disease. Specifically, CCL6, RARR
ES2, and CCL9/10 showed the highest level at initial
stage of disease (2 weeks) in the DM but reached the
maximum only in acute phase (3 weeks) in the GCM.
For the same token, IL6 level had modest increase at 2
weeks in the DM and was maintained at that level as
Fig. 1 Proteome analysis of chemokines in muscles of CMD-affected patients. The data were collected from independent arrays with duplicate
measurements for each chemokine using 5 BM, 8 UCMD, and 5 MDC1A muscle samples (Table S1). Chemokines are listed below the columns.
Data are presented as a mean pixel density ± SD. Statistical significance (p < 0.05) is indicated by asterisk. CMD types are indicated in the key. N,
normal (control); BM, Bethlem myopathy; UCMD, Ulrich congenital muscular dystrophy; MDC1A, Merosin-deficient congenital muscular dystrophy
type 1A
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disease progressed; however, its level did not change sig-
nificantly and was steady in the GCM. CCL8 and CCL12
levels dis not vary much and demonstrated consistent
pattern associated with all disease stages. Contrary, ana-
lysis of serum samples did not produce any noticeable
changes in chemokine profile despite disease progres-
sion; however, the serum collected from 1-week-old ani-
mals showed temporal increase in CCL6 (5.6-fold),
CXCL5 (4.9-fold), and CCL9/CCL10 (9.0-fold), which
reached the basal level by second week of life (data not
shown). Together, these data suggest that rapid induc-
tion and sustained expression of several chemotactic
molecules in the GCM and DM of LAMA2-deficient
mice may provide a selective mechanism for inflamma-
tory cell recruitment and, thus, play a role in disease
pathology. Also, identified chemotactic signatures sug-
gest that therapeutic stem cells can be recruited to the
affected tissues by the similar chemotactic mechanism as
immune cell trafficking.
Proteome analysis of chemokines in COL6-deficient mice
under physiological and pro-inflammatory conditions
The homozygous Col6a1−/− mutants completely lack
COL6 in the tissues but have normal life span. Skeletal
muscles of adult Col6a1−/− mice display a myopathic
histology, including fiber necrosis, phagocytosis, a pro-
nounced variation in the fiber diameter, and signs of
stimulated regeneration of fibers with necrotic fibers
particularly frequent in the diaphragm [20]. Since the
muscle phenotype of the Col6a1−/− mice is much milder
than that of the human UCMD patients, CTX was used
to exacerbate the temporal muscle abnormality, as previ-
ously shown in this model [22]. CTX selectively injures
myofibers but leaves nerves, blood vessels, and satellite
cells morphologically intact. Proteome profile was
undertaken to define a signature of chemokine release
corresponding to sequential stages of skeletal muscle in-
jury and regeneration. Following CTX treatment, the
GCM biopsies were harvested at defined periods (0/un-
injured, 1, 3, 7, 14, and 21 days). Assay controls con-
sisted of data collected from the age-matched wild-type
mice under similar treatment conditions. Data is pre-
sented as the fold-change difference of densitometry
reads between the Col6a1−/− and control groups. Com-
parative proteome profiling of the Col6a1+/+ and
Col6a1−/− GCMs under uninjured conditions showed
considerable presence of several chemokines in
Col6a1−/−-derived muscles, including Ccl21 (4.0-fold),
C5/C5a (18.1-fold), RARRES2 (8.4-fold), IL16 (11.9-fold),
Ccl2 (29.3-fold), Ccl8 (8.7-fold), Ccl12 (22.3-fold), Cxcl1
Fig. 2 Proteomic screens of chemokines in muscles of dyW mice. Data were collected from independent arrays with duplicate measurements for
each chemokine using muscle biopsies from wild-type (a) and dyW (b) mice, respectively, at 1, 2, 3, 4, 5, and 6 weeks after birth. Time points are
indicated in the key. Chemokines are listed below the columns. Data are presented as a mean pixel density ± SD. w, week(s)
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(5-fold), and Cxcl12 (42.6-fold) (Fig. 3a and Table 3).
Twenty-four hours after CTX injury, a substantial re-
lease of several pro-inflammatory chemokines was evi-
dent in the wild-type GCM, as judged by increased
levels of Ccl6, C5/C5a, RARRES2, IL16, Cxcl5, Ccl8,
Ccl12, and Ccl9/Ccl10 (Fig. 3b). Interestingly, chemo-
kine profile of Col6a1−/− mice showed modest response
to CTX, affecting only a few molecules, including C5/
C5a, Cxcl1, Cxcl10, Ccl8, and Ccl9/Ccl10 (Fig. 3c).
Moreover, the level of induced chemokines was compar-
able between wild-type and Col6a1−/− muscles, with the
exception of Ccl21, C5/C5a, Cxcl10, and Cxcl12
(Table 3). Further analysis of regenerating muscles
showed that the levels of CTX-induced chemokines in
wild-type GCM were reestablished to the baseline values
by 2weeks after injury. In contrast, high levels of CTX-
induced chemokines in Col6a1−/− mice persisted for 2weeks
until they restored to the basal level by week 3 (Table 3).
Chemotaxis-mediated recruitment of ADSC to skeletal
muscles in vivo
Our previous FACS-based assessment of receptor activ-
ity in minimally cultured primary stem cells showed that
ADSC have very limited percentage of cells with func-
tional chemokine receptors, accounting for their inef-
fective recruitment into muscles [21]. Because homing
of systemically infused ADSC to the muscle could be en-
hanced via the use of cells uniformly expressing princi-
pal receptor, ADSC engineered to express Ccr2 were
systemically transplanted into NCr nude mice followed
by localized intramuscular administration of the mouse
recombinant Ccl2 chemokine into the left GCM. As ex-
pected, mice transplanted with heterogeneous ADSC
(less than 6% of cells positive for Ccr2 receptor) showed
significant cell entrapment in lungs during first 24 h,
with no detectable engraftment into chemokine-treated
or untreated limbs (Fig. 4a). In the next 48–72 h, control
mice did not show any appreciable signals, indicating
exiting of cells along unspecific axes within the body
(Fig. 4b, c). In sharp contrast, as early as 24 h after trans-
plantation, migration of Ccr2-postive ADSC along cre-
ated chemotactic gradient was observed in the
chemokine-treated GCM but not in untreated right limb
(Fig. 4d). Additional 48 h led to a more robust migration
of the receptor-expressing cells from the circulation to the
chemokine-treated muscle, as revealed by the marked in-
crease in red fluorescent signal (Fig. 4e, f). Direct im-
munofluorescence analysis of muscle biopsies showed
preferential colonization of Ccr2-positive ADSC around
blood vessels (data not shown). Taken together, these
findings strongly support our hypothesis that engagement
of stem cell receptor with tissue-derived chemokine is a
critical step in cell recruitment into muscle tissue.
Chemotactic recruitment of ADSC to CMD-affected
muscles
Comparative proteome analysis of human and mouse
CMD samples as well as pairwise matching of identified
chemokines and their cognate receptors allowed us to
identify few common chemotactic axes, including
CXCL7/CXCL1,2,3-CXCR2 and CCL2-CCR2, as poten-
tial gradients for targeting of ADSC into CMD muscles.
Chemotactic activity of ADSC uniformly expressing
CMD muscle-specific chemokine receptors was assessed
in a pre-clinical setting using the COL6 deficient mouse
model. Reinstatement of COL6 deposition in skeletal
muscles was examined after systemic transplantation of
selected Ccr2- and Cxcr2-positive ADSC (1.5–2 × 106/
injection/mouse) fluorescently labeled with DiOC18
Table 2 Proteome analysis of chemokines in muscle biopsies of
dyW mice
Chemokine Fold difference/controla
Time since birth, weeks
1 2 3 4 5 6
CCL21 3.4 2.1 3.8 6.0 6.4 4.7
CXCL13 1.5 0.2 0.7 2.7 1.3 0.6
CCL6 5.6 6.6 6.0 7.1 7.0 17.0
C5/C5a 6.8 6.3 23.1 12.3 6.8 14.0
CCL28 1.5 2.6 3.5 3.7 4.0 3.2
RARRES2 1.6 1.9 6.3 8.6 7.4 76.2
CCL27 9.7 6.6 10.3 19.6 8.0 14.2
CXCL16 2.5 1.8 2.5 3.0 2.7 4.1
CCL11 5.1 1.3 2.5 3.8 1.3 3.2
CX3CL1 53.6 1.2 1.4 4.4 1.6 2.2
IL-16 4.2 3.9 4.3 9.9 7.3 20.1
CXCL10 2.6 2.4 4.0 7.9 4.6 6.5
CXCL11 2.1 3.8 2.8 3.7 2.0 4.8
CCL2 6.5 5.5 4.2 9.5 5.5 15.2
CXCL1 7.4 6.3 7.3 10.8 5.1 12.5
CXCL5 2.0 1.0 4.9 6.0 1.7 2.5
CCL8 7.7 11.4 18.3 3.0 4.4 23.5
CCL12 5.5 5.1 4.0 8.0 5.7 11.3
CCL22 12.7 3.0 4.9 9.9 10.5 5.6
CXCL9 3.5 2.6 3.7 4.2 5.2 4.0
CC3/CCL4 14.6 2.2 4.3 3.9 8.5 13.0
CCL9/CCL10 11.5 15.0 41.2 10.6 14.2 47.3
CXCL2 5.4 1.6 8.1 1.5 3.3 3.1
CCL5 1.6 0.9 12.6 4.6 2.6 2.2
CXCL12 11.7 4.3 7.0 12.1 6.0 14.1
aData represented as fold difference of dyW muscle vs muscle from age-
matched wild-type counterpart (control). Each protein array was processed in
an identical manner and the number represents an average of triplicate
experiments from 5 pooled muscle biopsies. Fold difference does not
reflect quantity
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under physiological and CTX-induced inflammatory
conditions, respectively. The right GCM was injected
with CTX and left GCM was injected with PBS and
served as control for natural homing followed by cell
transplant 24 h after injury. To compare potential of se-
lected ADSC in normal and muscle-damaged condition,
mice were also treated with unselected ADSC in a simi-
lar fashion. Live imaging of both CTX-treated and con-
trol limbs was performed at 4 (dorsal view), 14, and 21
(ventral view) days after cell transplantation. The experi-
mental animals were concluded 3 weeks after a single
transplant. The mice transplanted with heterogeneous
ADSC did not show any appreciable signals (data not
shown). Contrary, the red fluorescent signals of
DiOC18/Ccr2- and DiOC18/Cxcr2-positive ADSC were
detectable in all transplanted animals and persisted for
the entire study, suggesting the efficient homing and en-
graftment of cells in the muscle environment under the
influence of chemokines in both physiological and CTX-
injured conditions (Fig. 5a). Moreover, the detected
fluorescent signals were significantly higher in the limbs
treated with CTX. Interestingly, the transplantation with
Cxcr2-positive ADSC (Cxcl1/Cxcr2, Cxcl2/Cxcr2, and
Cxcl5/Cxcr2 axis) resulted in more efficient migration
than Ccr2-positive ADSC (Ccl2/Ccr2 axis) (Fig. 5a, b).
This is in good agreement with our chemokine protein
array profiles showing the significant induction of Cxcl1,
Cxcl2, and Cxcl5 chemokines after CTX injury, which are
all potent chemoattractants for Cxcr2-positive inflamma-
tory cells. Direct immunofluorescence analysis of muscle
biopsies at 21 days after transplant revealed significant
presence and wide distribution of DiOC18-ADSC in
muscle interstitium (Fig. 5c). Co-immunostaining with
antibodies against COL6 and LAMA2, which is an integral
component of the muscle basement membrane, showed
overlapping fluorescent signals of both proteins at the
basement membrane of individual myofibers in both
Ccr2- and Cxcr2-positive transplants. Morphometric
Fig. 3 Proteomic screens of chemokines in muscles of Col6a1−/− mice under physiological and pro-inflammatory conditions. a Data were
collected from independent arrays with duplicate measurements for each chemokine using muscle biopsies from wild-type and Col6a1−/− mice,
respectively, under physiological conditions (−CTX). b, c Data were collected from independent arrays with duplicate measurements for each
chemokine using muscle biopsies from wild-type (b) and Col6a1−/− (c) mice, respectively, under pro-inflammatory conditions (+CTX). Post-injury
time points (days) are indicated in the key. Chemokines are listed below the columns. Data are presented as a mean pixel density ± SD. Statistical
significance (p < 0.05) is indicated by asterisk. d, day(s)
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analysis showed that the number of COL6-labeled myofi-
bers was greater in Cxcr2-positive ADSC transplanted
mice (Fig. 5d). Together, these findings strongly suggest
that stem cells uniformly expressing specific receptors can
be efficiently targeted to the CMD-affected skeletal muscle
under influence of the CMD muscle-derived chemotactic
signals.
Discussion
CMD pathogenesis is associated with the lack or dys-
function of the ECM, which provides support and pro-
tection from the shearing forces of muscle contraction.
We have suggested that ADSC known to produce vari-
ous ECM molecules, including collagen VI, could be
used as cellular therapeutics for this hereditary disorder.
Our prior studies on localized transplantation of ADSC
into CMD-affected muscle of mice mimicking Col6a1-
dependent COL6RM confirmed feasibility of ADSC-
based therapy. Considering an involvement of the whole
body musculature in the pathogenesis of this disorder,
systemic approaches are needed for an effective clinical
application. The primary challenge in the therapeutic ap-
plication of stem cells for CMD is the inefficient recruit-
ment of therapeutic cells to the damaged muscles. The
precise mechanisms responsible for adult stem cell mi-
gration to skeletal muscles in normal and pathological
conditions are still largely unknown but recent studies
suggested that chemokines are important players in skel-
etal muscle regeneration [23]. It was shown that experi-
mentally injured skeletal muscles and dystrophic
muscles of mdx mice are characterized by an inflamma-
tory “molecular signature” in which CC and CXC che-
mokines are prominent [15, 16]. To date, no sufficient
data is available regarding chemotactic signatures in
CMD-affected muscles either in patients or in animal
models. Chronic inflammation plays an important role
in the pathogenesis of CMD. One of the critical features
of inflamed muscle tissue is continuous infiltration of
muscles with leukocytes under the guidance of chemo-
kines, which define type and degree of inflammation. In
this study, we investigated chemotactic gradients of
CMD-affected muscle tissues from CMD patients and
CMD animal models, and defined chemotactic axes,
which could be employed for the targeting of therapeutic
ADSC to inheritably weakened muscle tissue.
Comparative proteome analysis indicates that levels of
CCL5, CXCL6, CXCL7, CCL2, and GRO are signifi-
cantly elevated in muscle biopsies from COL6RM and
MDC1A patients as compared to control muscle. These
data suggest that this set of chemokines is available to
provide an appropriate chemotactic gradient to direct
therapeutic ADSC to patients’ muscle tissue. All identi-
fied molecules are prominent chemotactic factors that
activate and attract various inflammatory leukocytes.
In contrast to the CMD patients, proteome analysis of
muscle biopsies from dyw and Col6a1−/− mice revealed
the significant induction of many chemokines. These
findings in the dyw model are consistent with observa-
tions that the dyw model presents with a severe pheno-
type correlating to the pathology of human MDC1A.
This is in contrast to the Col6a1−/− mouse model, which
produces no detectable COL6 protein, but displays a
mild phenotypic severity when compared to human
UCMD and more similar to the milder BM. Therefore,
to explore chemotactic recruitment of ADSC from the
systemic compartment, induction of the inflammatory
process in the Col6a1−/− mouse was accomplished
through administration of a myonecrotic agent, the Naja
mossambica mossambica venom CTX, which causes
Table 3 Proteome analysis of chemokines in muscle biopsies of
Col6a1−/− mice
Chemokine Fold difference/controla
Time after CTX treatment, days
0 1 3 7 14 21
Ccl21 4.0 3.8 3.3 2.7 6.3 5.5
Cxcl13 1.1 1.1 1.1 1.1 1.1 1.1
Ccl6 1.3 1.2 1.1 0.9 2.0 1.6
C5/C5a 18.1 3.0 9.6 19.9 80.2 23.0
CCL28 1.1 1.2 1.1 1.2 1.1 1.3
RARRES2 8.4 1.5 3.0 4.8 7.7 6.0
Ccl27 13.9 3.2 8.3 5.5 6.0 3.0
SRPSOX 1.1 1.2 4.8 1.1 1.2 1.1
Ccl11 1.1 1.2 1.1 1.1 1.2 1.1
Cx3cl1 1.1 1.1 1.1 1.1 1.1 1.1
IL16 11.9 1.1 1.5 5.1 36.4 14.6
Cxcl10 10.5 39.6 45.6 10.2 1.1 1.1
Cxcl11 1.1 1.1 1.1 1.1 1.1 1.1
Ccl2 29.3 12.2 15.4 18.9 13.1 16.7
Cxcl1 1.2 1.1 1.1 1.2 1.1 1.2
Cxcl5 1.2 4.3 1.1 1.2 1.1 1.2
Ccl8 8.7 1.6 4.4 1.2 48.7 7.5
Ccl12 22.3 1.5 14.7 6.8 35.9 20.9
Ccl22 1.1 1.1 1.2 1.1 1.2 1.1
Cxcl9 1.1 1.1 1.2 1.1 1.2 1.1
Ccl3/Ccl4 1.1 1.1 1.2 1.1 1.2 1.1
Ccl9/Ccl10 0.9 1.3 1.1 0.9 5.4 1.6
Cxcl2 1.2 1.1 1.2 1.1 1.2 1.1
Ccl5 1.1 1.1 1.2 1.1 1.2 1.1
Cxcl12 42.6 38.4 182.8 47.7 45.6 47.7
aData represented as fold difference of Col6a1−/− muscle vs muscle from age-
matched wild-type counterpart (control). Each protein array was processed in
an identical manner and the number represents an average of triplicate
experiments from 5 pooled muscle biopsies. Fold difference does not
reflect quantity
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selective damage by targeting myofibrils and inducing
inflammation, as previously shown in the same model
[22]. After CTX administration, many chemokines identi-
fied in LAMA2-deficient muscles were also present in
CTX-damaged muscle of Col6a1−/− mice, suggesting that
both diseases share similar chemotactic signals in mice.
Rapid induction and sustained expression of identified
chemotactic molecules in CTX-injured muscles suggest
that chemotaxis could serve as a primary mechanism for
continuous and selective recruitment of chemokine
receptor-positive inflammatory and therapeutic cell.
Although a precise role of the identified chemotactic
molecules in CMD pathology remains to be identified, it
is likely that the pattern and the level of specific chemo-
kines in different CMD pre-define inflammatory infil-
trate and degree of muscle injury. Our data showing
elevated levels of several CC-motif-containing chemo-
kines extend prior studies showing increased expression
CCL2, CCL3, and CCL4 in muscle biopsies obtained
from animal models and human patients suffering from
muscular dystrophy or inflammatory myopathies [23].
Besides playing a role in CMD pathology, some of these
chemokines could be attractive for the targeting of
therapeutic ADSC from circulation into chronically in-
jured CMD-affected muscles. For example, CCL2-
mediated chemotaxis is critical for tissue recruitment of
monocytes/ macrophages upon inflammation and infec-
tion. It exerts its activity via interaction with CCR2 receptor
and plays a pathogenic role in chronic inflammatory dis-
eases, including multiple sclerosis, atherosclerosis, and
rheumatoid arthritis [24]. Conversely, CCL2-mediated in-
flammatory response is essential for repair of acute skeletal
muscle injury. Ccr2−/− mice and mice receiving antibodies
against CCL2 show markedly reduced macrophage infiltra-
tion in response to acute muscle injuries induced by ische-
mia or myotoxic agents, and the diminished inflammatory
response is accompanied by poor muscle regeneration [25].
CCL5, also known as RANTES (Regulated upon activation,
normal T cell expressed, and secreted), plays an essential
role in leukocytes (monocytes, macrophages, T cell subsets,
DCs, eosinophils, and basophils) homing to the sites of in-
flammation [26]. It can also stimulate eosinophils to secrete
eosinophil cationic protein and stimulate basophils to re-
lease histamine. In collaboration with T cell-derived
Fig. 4 Representative live imaging of Ccl2/Ccr2-mediated recruitment of systemically transplanted heterogeneous ADSC (a, c, e) and Ccr2-positive
ADSC (b, d, f) into the GCM of NCr nude mice. Mouse recombinant Ccl2 chemokine was administered into the left GCM immediately after cell
transplant. Cell recruitment to the muscle was assessed by luciferase fluorescence at 24, 48, and 72 h after transplantation, respectively. Oval
demarcates luciferase-ADSC fluorescence. Asterisk in oval indicates Ccl2 chemokine injection site
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cytokines (e.g., IL-2 and IFNγ), it can also activate NK cell.
This chemokine plays an important role in a large number
of inflammatory, allergic, autoimmune, or infectious dis-
eases. CCL5 mediates its chemotactic activity through bind-
ing to CCR1, CCR3, and CCR5 receptors on the cell
surface. As CCR5 serves as HIV-1 co-receptor, a number of
inhibitors have been design to block CCR5. However, only
a few studies aimed at development of CCL5 inhibitory
strategies for different inflammatory disorders were con-
ducted [27]. Our data showing significantly elevated CCL5
level in CMD-affected muscles, suggest that CCL5 could be
a novel therapeutic target for CMD and that its inhibition
could attenuate CMD-associated inflammation and fibrosis.
This view is indirectly supported by our data showing that
CCL5 levels are associated with CMD severity with the
lowest levels in BM samples and the highest LAMA2 biop-
sies. Although these observations also support a prognostic
value of this chemokine for CMD severity assessment, fur-
ther evaluation and biostatistical analysis of this chemo-
kines in biopsies and blood samples of a larger cohort of
patients will be required. Other upregulated CC-motif con-
taining chemokines including RARRES2 (also known as
chemerin), CCL8, CCL9/CCL10, and CCL6 (identified only
in rodents) are potent chemoattractants for different leuko-
cytes including monocytes, macrophages, eosinophils, baso-
phils, NK, and T cells. Majority of these ligands are
chemotactic to cells expressing CCR1, CCR2, and CCR5
receptors.
Assessment of chemotactic signals in CMD-affected
muscles also showed that the majority of significantly
Fig. 5 Systemic transplantation of selected ADSC into Col6a1−/− mice. a Representative in vivo images showing the hindlimbs of mice receiving
Ccc2-positive ADSC and Cxcr2-positive ADSC transplants under physiological (−CTX) and pro-inflammatory (+CTX) conditions, respectively. IVIS
live imaging was performed at 4, 14, and 21 days post-transplant. b Quantitative analysis of fluorescence detected by live imaging from differently
treated cohorts of mice (n = 3 per time point) at 3 time points (as indicated below the columns). Data are presented as radiant efficacy ± SD and
as fluorescent area ± SD, respectively. Color-coding for Ccr2-positive ADSC and Cxcr2-positive ADSC is shown in the key. Dotted trend lines
illustrate time-dependent changes in differently treated mice, as indicated in the key. Statistically significant differences in Ccr2- and Cxcr2-
positive ADSC-treated mice (p < 0.05) are indicated with asterisks (***). c Immunofluorescent analysis of GCM tissue from untreated and CTX-
treated muscle biopsies was performed 21 days after transplantation. Co-localization of the ADSC-donated COL6 and basement membrane-
associated type IV collagen was detected with α1(VI) collagen (AlexaFluor488, green) and LAMA2 (AlexaFluor594, red) antibodies. Images were
taken from representative sections at low and high (20x) magnification, respectively. Nuclei were stained with DAPI (blue). Scale bar, 100 μm (low
magnification) and 25 μm (high magnification), respectively. d Quantitative assessment of COL6-positive myofibers on sections of muscle tissue
from mice treated with unselected ADSC, Ccr2-positive ADSC, and Cxcr2-positive ADSC, respectively. Data are presented as the percentage of
COL6-positive myofibers per microscopic field ± SD. Time points of tissue collection and treatments are indicted below the columns. Statistical
significance (p < 0.05) is indicated with asterisks (***)
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upregulated CXC-motif-containing chemokines transmit
their chemotactic activity via CXCR1 and CXCR2 che-
mokine receptors. This group includes GRO family che-
mokine (CXCL1, CXCL2, CXCL3), CXCL7, and CXCL8.
All of them involved in neutrophils, macrophages and
others cell of myeloid origin. The functions suggest that
these chemokines could not only exacerbate CMD
muscle inflammation but also promote its chronicity by
constitutively attracting and activating these cells. As
shown in models of muscular dystrophies and other my-
opathies, both neutrophils and macrophages have a cap-
acity to kill muscle cells [28], and their presence was
associated with an aggravated of muscle pathology [29].
These data along with our findings are in a good agree-
ment with a recently published study showing that mus-
cles of UCMD patients are significantly infiltrated with
M2 macrophages [30]. CXCL12 is another CXC-motif
chemokine upregulated in mouse CMD muscles. This
molecule is chemotactic for T cells and monocytes dur-
ing acute inflammatory responses [31]. CXCL12 stimu-
lates migration of monocytes and T-lymphocytes
through its receptors, CXCR4, and plays a significant
role in regulating migration of both proliferating and
terminally differentiated muscle stem cells. Inhibition of
this axis was associated with impaired migration and in-
creased apoptosis of skeletal muscle progenitor cells dur-
ing embryogenesis [32].
Considering proteome data, we suggested that CCR2
and CXCR2 could be the key receptors to direct CMD
muscle-specific migration and homing of ADSC. The
capacity of systemically administered ADSC to partici-
pate in regeneration of skeletal muscle was evaluated
using the CTX-induced myonecrosis model with actively
ongoing regeneration and remodeling of muscle tissue.
Our data clearly demonstrated that both CCR2 and
CXCR2 receptors provided directional migration of the
systemically administered ADSC into injured muscles.
Both, CCR2- and CXCR2-positive ADSC were retained
in the muscle for a considerable time (3 weeks of obser-
vations), suggesting that transplants were homed to the
tissue. However, based on quantitation of live imagings,
CXCR2-positive ADSC were twice more effective in
homing into muscles than CCR2-positive cells. As illus-
trated by the trend lines (Fig. 5b), CXCR2 receptor pro-
vided sustainable presence of ADSC in muscle tissue. In
part, this could be explained by a higher number of up-
regulated CXCR2 ligands in CTX-injured muscles. This
sustainability could also result from different molecular
events involved in recruitment of cells from circulation
into the tissue. This process involves chemokine-
mediated binding of cells to the endothelial lining of the
lumen of the blood vessels following extravasation of
cells through the vessel wall and migration within the
tissue [33]. Considering that CXCR2 ligands are released
by endothelial cells of vasodilated blood vessels to re-
cruit leukocytes to the sites of inflammation, it is plaus-
ible that extravasation of CXCR2-positive cells is more
efficient than CCR2-positive ADSC due to stronger ex-
travasation signals provided by CXCR2 ligands. More-
over, COL6-producing CXCR2-posotive ADSC migrated
intramuscularly more efficiently. As illustrated by the
trend lines (Fig. 5b), there is a continuous increase in
the area covered by CXCR2-positive ADSC. This obser-
vation suggests that CXCR2 ligands, which are widely
expressed throughout the damaged muscle, also provide
sufficient chemotactic signals for intramuscular migra-
tion of the transplanted cells. In addition, CXCR4-
CXCL12 chemotactic axis may also play an important
role in the intramuscular migration of ADSC. Our ana-
lysis showed elevated expression of CXC12 in CTX-
injured and CDM muscles. Taking together these data
with prior observations showing CXCL12-mediated in-
duction of its receptors on ADSC [34], it is plausible that
once ADSC are recruited to the damaged muscles,
CXCL12-CXCR4 axis could enhance intramuscular mi-
gration of the therapeutic cells. This notion is indirectly
supported by prior data showing that CXCL12-CXCR4
axis regulates migration of both proliferating and ter-
minally differentiated muscle cells [35].
Significant impact of chemokine receptor-mediated
targeting of systemically infused ADSC on the thera-
peutic effect is also supported by the assessment of the
COL6-positive myofibers in differently treated mice.
Thus, very few COL6-positive myofibers were found in
CTX-injured muscles treated with unselected ADSC,
whereas more than 60% of COL6-positive myofibers
were found in CTX-injured muscles 14 days after trans-
plantation of CXCR2-positive ADSC (Fig. 5d). Sustain-
ability of COL6 donation to the myomatrix of injured
muscles for at least for 21 days of observation period
strongly supports the utility of stem cell therapy for
COL6RM, which exhibits substantially more severe myo-
pathology than the mouse model.
Conclusion
Analysis of human and mouse CMD-affected muscles
revealed a number of upregulated chemokines that could
play an important role in CMD pathology and that
CCL5-CCR1/3/5, CCL2-CCR2, and CXCL1/2/7/8-
CXCR1,2 chemotaxis axes could be used for the target-
ing of therapeutic cells to the injured CMD muscles.
Comparison between CCR2- and CXCR2-positive ADSC
populations demonstrated that both receptors provided
muscle-specific homing of therapeutic cells. Moreover,
CXCR2-mediated recruitment was more potent in
directing ADSC to the injured muscle, in the intramus-
cular migration, and donation of the therapeutic COL6
protein into the myomatrix. Collectively, our data
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demonstrated that a systemic administration of stem
cells expressing pre-defined set of chemokine receptors
could be beneficial to counteract the disease phenotype
in CMD-affected muscles. Further mechanistic studies
to identify critical factors involved in chemotactic-based
directional migration of the stem cells will hopefully
pave the way for designing rational approaches toward
increasing the disease-site targeting efficiency.
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